Objective. Intrathecal baclofen (ITB) has become the first choice in the management of deleterious spasticity that does not respond to oral and intramuscular medications following spinal cord injury, traumatic brain injury, and cerebral palsy. The usefulness of ITB in severe spastic hemiparesis following stroke is studied. Methods. A total of 8 patients underwent clinical and video assessment following ITB bolus application (n = 5) and during continuous infusion via a temporary catheter system (n = 3). Results. The mean daily dosage alleviating spasticity on the hemiparetic side-without affecting the nonparetic side-was 119 µg/day (range 50 to 360 µg/day). However, 6 patients experienced functional deterioration as ITB weakened their paretic side such that the antigravity pattern they used for ambulation was suppressed. In 2 patients, spasticity-associated pain and spasms subsided and they underwent implantation of a long-term drug delivery system. Conclusions. ITB may reduce spasticity in a dose-dependent manner irrespective of its origin. Although not primarily antinociceptive in humans, ITB may alleviate pain if arising from increased muscle tone. A functional benefit may result if ITB can uncover "subclinical" motor control that had been suppressed by spasticity. However, when a patient uses antigravity patterns for ambulation in the absence of more complex motor control, ITB may cause the loss of residual walking ability, which becomes a major limitation for patients with hemiplegic stroke.
I ntrathecal baclofen (ITB) application has become the first choice in the pharmacological management of spasticity that cannot be reduced by oral medications following spinal cord injury, 1,2 traumatic or hypoxic brain injury, [3] [4] [5] and cerebral palsy. 6 Recent reports suggested that ITB was also capable of effectively suppressing spasticity on the affected side without reducing muscle strength on the nonparetic side in patients with hemiparesis due to acquired brain injury and stroke. [7] [8] [9] Yet, not all patients with cerebral lesions may benefit from the reflex-altering antispasticity effects of baclofen. 10 A spastic extensor synergy may help to bear body weight in a weakened leg, thereby enabling ambulation in selected hemiplegic patients. 11 Therefore, the administration of ITB in hemiparesis has been a focus of controversy. 11, 12 In particular, in the few studies that address the effect of ITB on ambulation in spastic patients, 8, [13] [14] [15] [16] careful patient selection has been advocated when the goal is to improve walking. We investigated ITB in ambulatory hemiparetic stroke patients to functionally improve their gait abilities. Our aim was to clinically identify patients who may benefit from ITB and those who do not, based on functional indicators elaborated in a common effort by neurorehabilitation specialists and physiotherapists. We give an account of our experience with the limited utility of ITB in patients with severe spastic hemiparesis following stroke.
Patients and Methods
A total of 8 patients (mean age 45 years, range 11 to 64 years) with predominantly unilateral stroke (ischemic or hemorrhagic) have been consecutively recruited since 1996 from our rehabilitation clinic after obtaining informed consent. All patients were diagnosed with severe chronic spastic hypertonia in the contralateral upper and lower extremity lasting at least 6 months (Table 1) . Mean age at onset of stroke was 45 ± 17.5 years (mean ± standard deviation). Clinical examination focused on the affected side and included assessment of muscle tone (Modified Ashworth Scale, MAS 7 ) and muscle strength (Medical Research Council Scale, MRC Scale 17 ), both for shoulder adduction and abduction, as well as flexion and extension in elbow, wrist, hip, knee, and ankle. Tendon reflexes were assessed in elbow and knee joints on the affected side using the Reflex Scale. 7 All measurements were obtained with patients lying supine in bed, with elbows and knees slightly flexed. The presence of painful spasms was noted 7 based on observation and questions. Gait function was assessed in the gait laboratory with Rivermead Visual Gait Assessment Form 18 and Modified EU Walking Scale. 19 Sensory deficits were clinically assessed but not formally rated; 6 patients had hemihypesthesia, 2 did not. Patients were enrolled when they presented with mean MAS and Reflex scores of 3 or more, averaged across all tested joints in the upper and lower limb on the affected side but normal muscle tone and strength on the nonparetic side.
All patients had received high-dose oral antispasticity medication including baclofen, tizanidine, and diazepam, to no avail and with intolerable adverse effects. All patients underwent serial clinical assessment by the same investigator at baseline and 3 to 5 hours following a 50 µg (n = 5), 75 µg (n = 1), and 100 µg (n = 2) ITB bolus (bolus-ITB) or following dose adjustments during continuous infusion via a temporary catheter system (continuous-ITB; n = 3). Muscle tone, tendon reflexes, and muscle strength were assessed daily by experienced neurologists, and the gait function was assessed daily by physical therapists. Statistical comparison of scores obtained at baseline and following the highest dosage of bolus-ITB or continuous-ITB was performed using the Wilcoxon test. Comparison of independent variables was performed with the Mann-Whitney U test.
Results
The mean daily dosage of ITB alleviating spasticity on the hemiparetic side without clinically affecting the nonparetic side was 119 µg/day (range: 50 to 360 µg). Effective bolus administration (n = 5) ranged from 50 to 100 µg, whereas continuous infusions (n = 3) reached 96 to 360 µg/day ( Table 2) . ITB reduced overall MAS scores across all 6 joints tested from 3.69 ± 0.62 to 2.50 ± 0.68 (P < .001). Separating upper and lower extremities revealed a trend toward more reduction of MAS scores in the lower extremities (from 3.71 ± 0.62 to 2.38 ± 0.71; P < .001), than in the upper extremities (from 3.67 ± 0.64 to 2.63 ± 0.65, P < .001) ( Figure 1 ). Similarly, overall Reflex scores were effectively reduced from 3.6 ± 0.6 at baseline to 2.1 ± 0.6 during ITB application (P < .001), with a similar trend toward more effect in the lower extremities ( Figure 1 ). Overall muscle strength, as assessed with the MRC Abbreviations: M, male; F, female; ACA, anterior cerebral artery; MCA, middle cerebral artery; PCA, posterior cerebral artery; R, right hemisphere; L, left hemisphere.
Figure 1 Assessment of Muscle Tone (Modified Ashworth Scale, MAS), Tendon Taps (Reflex Scale), and Muscle Strength (Medical Research Council Scale, MRC Scale) in the Upper (A) and Lower (B) Extremities on the Affected Side in 8 Stroke Patients at Baseline and During Intrathecal Baclofen (ITB) Application
Scale, did not significantly change during ITB application ( Table 2 ). There was, however, a significant reduction of muscle force in the lower extremities (from 2.9 ± 1.3 to 2.4 ± 1.2; P = .002) ( Figure 1 ). No significant difference was observed between patients receiving bolus-ITB versus continuous-ITB with regard to reduction of MAS, Reflex, or MRC scores (P > .1 each). The most striking impact of ITB, however, was observed on ambulatory function: the Modified EU Walking Score was significantly reduced by ITB (P = .023). A total of 4 patients, who were independent walkers either unaided or with a cane, required a cane plus personal assistance during ITB application, and 2 other patients deteriorated to a condition requiring maximum assistance ( Table 3 ). The main reason for worsened ambulation was a reduction in motor control in the hip and knee. In contrast, sensory disturbances seem to have played a lesser role in the decline in ambulation, as those patients with hypesthesia did not functionally deteriorate more than those without. ITB did not alter ambulatory function in only 2 patients, of whom one was capable of walking with a cane, whereas the other was unable to walk unaided with and without ITB ( Table 3 ). Both of these patients also suffered from severe spasticity-associated pain. As ITB effectively suppressed their involuntary spasms, thereby alleviating pain as well, these 2 patients underwent implantation of a pump system. Notably, the deterioration in gait function was not adequately reflected by the Rivermead Visual Gait Assessment Form.
There was no significant change before and during ITB application (P = .73).
No patient encountered seizures, respiratory suppression, clinically relevant alterations in blood pressure and heart rate, or reduced vigilance during the evaluation period. Urinary hesitancy led to a residual volume of 800 mL requiring temporary catheterization in a patient receiving a 100 µg bolus of ITB. A total of 2 patients reported transient vertigo and subjective tiredness.
Discussion
Baclofen is a γ-aminobutyric acid (GABA) agonist that binds to presynaptic GABA B receptors throughout the central and peripheral nervous system. Relevant sites for antispasticity effects are considered to be located in superficial layers of the dorsal horn of the spinal cord. 20 Although baclofen is a lipophilic substance that is rapidly and completely absorbed after oral administration, it barely passes the blood-brain barrier. 21, 22 Thus, only a fraction of baclofen is distributed to the spinal cord dorsal horn where it would be desired, whereas a relatively large amount is distributed throughout the body where it may cause unwanted effects. When oral administration fails to be sufficiently effective, intrathecal application of only a fraction of the oral dose by means of implanted pump systems may be a powerful alternative approach. [1] [2] [3] [4] [5] [6] Notably, however, there is large interindividual pharmacokinetic variation as reflected by the lack of correlation between daily effective ITB dosage and corresponding baclofen concentration in the cerebrospinal fluid. 20 Meythaler et al 23 were the first to advocate the usefulness of ITB in hemiparetic patients, reporting a reduction, induced by a single 50 µg ITB bolus, of MAS score (at least 2 points), Reflex score, and Spasm score in 3 patients with traumatic brain injury and 3 patients following stroke. All patients underwent subsequent pump implantation but required on average 205.3 µg/day (range 100 to 500 µg/day) after 3 months to achieve the same effect. A total of 3 patients were reported to have improved their walking abilities. 23 No changes other than suppressed tendon reflexes were noted on the unaffected side. In a second series, the same authors reported similar findings in 22 stroke patients, of whom 17 underwent pump implantation, and 3 of them allegedly improved their walking abilities within 1 year, 7 but no formal rating was performed as to assess their walking abilities.
A more recent study reported improvement in walking speed in 10 poststroke patients. 8 The time interval between pump implantation and follow-up was 8.9 months (range 4 to 25 months), during which the patients received regular physical therapy. No data were provided as to the daily ITB dosage. In 6 of 10 patients, the functional mobility score was reported to be improved, but the functional walking category improved in only 2, whereas it deteriorated in 1 patient. 8 How much of the gait improvement over 8 months was due to ITB (of unknown dosage) and how much was due to regular physical therapy remains unclear, however.
In the present study, 6 patients (4 bolus-ITB, 2 continuous-ITB) experienced serious functional deterioration as ITB weakened their paretic side, causing a lack of motor control particularly at the hip and knee extensors. Thus, the antigravity pattern they had used for ambulation was suppressed to such a degree that they became dependent on walking aids or hands-on physical assistance or wheelchair-bound. This is reflected by their EU Walking Scale scores but not in the Rivermead Visual Gait Assessment scores (Table 3 ). This discrepancy could be explained by the fact that the latter includes many items describing the patient's posture and gait which are not ultimately responsible for the stability of functional walking. The stance phase was particularly affected, with loss of the extensor pattern necessary for maintaining the upright position during weight bearing on the affected side. Postural control and balance deteriorated, and in one case, lateral deviation to the affected side worsened extremely. Hip and knee extension were no longer adequately functional. Almost all of our patients deteriorated in their ambulatory pattern, leading to increased dependency on a cane or manual assistance. We have therefore adopted a more demanding view as to the utility of ITB in spastic hemiparesis: only 2 of our 8 patients underwent pump implantation, which aimed to reduce pain associated with spasms.
In patients with severe spasticity, some residual motor control may be masked. ITB treatment may uncover such subclinical motor control and lead to functional improvement. Such functional benefits due to ITB treatment have previously been observed in bedridden patients, whose mobility improved to enable them to sit in a chair, and in patients suffering from severe spasm-related pain. 24 Little or no improvement in disability or perceived health status was noted, however, in patients with spinal cord injury or multiple sclerosis despite improved clinical status. 25, 26 In contrast, a large multicenter study of ITB in stroke patients reported significant improvement in function and quality of life but not in ambulation. 9 In our ambulatory patients, the preservation, if not improvement of walking ability was of utmost interest. Any deterioration in ambulation was considered to seriously interfere with activities of daily life. We therefore decided against permanent pump implantation in these patients. Other functions and aspects of quality of life were of comparably minor interest to us and to our patients. Those patients who do benefit from ITB in walking ability, that is, those who develop better control of the lower limb during the swing phase, may have less severe spasticity. In fact, baseline MAS scores were higher in our patients than in those previously reported by Meythaler et al, 7 Rémy-Néris et al, 16 and Francisco and Boake, 8 which may have contributed to the differences in functional outcome in our more severely affected patients. Studies in hemiparetic patients so far reported significant reduction in muscle tone in the affected limb, whereas there was no change in strength or coordination noted on the nonparetic side. Why the nonparetic limbs remain unaffected by ITB is still unclear: a selective effect of baclofen on certain spinal cord receptors that also receive supraspinal input modified by cerebral disease has been put forward. 12 In our experience, patients with poststroke spasticity with MAS scores of >3 likely depend on their extensor spasticity for ambulation. Alleviating their spasticity renders them nonambulatory due to unmasked weakness. Thus, when a patient uses antigravity patterns for ambulation in the absence of more complex residual motor control, ITB will likely be of little value and may worsen the patient's functional status. In contrast, patients with MAS scores <3 are likely to respond sufficiently to oral baclofen in a dose range of 10 to 80 mg/day, 11 possibly complemented by local chemodenervation with botulinum toxin, 11 thus not necessarily warranting the costly intrathecal treatment strategy and undergoing the risk of surgery. Francisco and Boake 8 suggested that physical therapy focusing on muscle strengthening, motor re-education, gait retraining, and control of spastic hypertonia may facilitate improvement in gait.
Less efficacy of ITB for upper as compared with lower extremity hypertonicity is well known; even cervical catheter placement has not been able to overcome this difference in a clinically meaningful manner. 27 Although continuous infusion of ITB via external pump and temporary catheter system allows for fine-tuning of the daily dosage in the test-phase, we observed no significant difference of the effects, particularly in ambulation, in comparison with ITB bolus application. An external pump system and tunneling of a temporary catheter for ITB evaluation for a longer period (up to 10 days) allows fuller assessment of muscle tone and reflexes, as well as alterations of intestinal function 28 and voiding, 29, 30 as seen in one of our patients. No adverse effects such as reduced vigilance, respiratory suppression, clinically relevant alterations in blood pressure and heart rate, or seizures were noted. [31] [32] [33] The role of ITB in the management of pain is controversial. Although most authors agree that ITB has no analgesic effect in humans per se, but may be beneficial if painful spasms are suppressed, analgesic effects of ITB in postherpetic neuralgia 34 and central pain caused by spinal lesions or following stroke have been reported. 35, 36 Two of our patients (1 bolus-ITB, 1 continuous-ITB) suffered severe spasticity-associated pain. When ITB efficiently controlled their spasms, their pain syndrome subsided. Ambulatory function did not change in either patient: one remained nonambulatory; the other was able to walk alone with a walking aid. Subsequently, both patients underwent implantation of a long-term drug delivery system for intrathecal application. In both, ITB enabled easier hygiene and improved activities of daily living.
In summary, contrary to previous reports, 7, 8, 23 we observed that ITB treatment was of only limited value in most patients suffering from severe spastic hemiparesis due to the high incidence of induced functional deficits, particularly related to walking ability. The expectations of success with ITB regarding antispastic efficacy may be unreachable due to biomechanical changes in muscle or the other predominating symptoms of the upper motor neuron syndrome, both positive and negative. We want to emphasize that we consider the limitations of ITB in ambulatory patients with stroke-related spasticity to be arising mainly from ITB's propensity to worsen ambulation. ITB treatment does have hygiene-spasm-pain effects when patients are not ambulatory. Thus, our findings underline the necessity in future studies of setting functional, patient-oriented goals in order to adapt the treatment to the individual needs of each patient. Two questions require more study: (1) whether less severely spastic hemiparetic stroke patients may be better candidates for ITB treatment when the aim is to improve mobility, and (2) whether intensive physical therapy during ITB treatment may serve to overcome stroke-related weakness aggravated by the weakening effect of ITB.
